This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Gaining insights into recent updates on menin inhibitors as monotherapies, and as combination drugs.
Ticker(s): SNDX, KURA, JNJ, DNPUFWho's the expert?
Institution: Huntsman Cancer Institute
- Assistant Professor in the Transplant and Cellular Therapy Program at Huntsman Cancer Institute
- Treats 20 patients with chronic GVHD a month
- Clinical and research expertise is in Blood and Marrow Transplantation and GVHD with particular interest in allogeneic hematopoietic cell transplantation as well as cellular therapies such as CAR-Ts for the treatment of malignant and benign hematologic diseases in adult patients
Interview GoalThis call will discuss the current treatment landscape and the potential of menin inhibitors being developed as monotherapies for treating a variety of leukemias.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 06, 2025
- Call Time
- 02:00 PM EST
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
